[Lessons from the novel renoprotective studies with antihypertensive drugs].

From the evaluated ONTARGET, ALTITUDE, ACCOMPLISH, ROADMAP, and ACCORD-BP studies a conclusion can be drawn that though microalbuminuria/proteinuria is a strong epidemiological biomarker, in interventional studies it is not necessarily a reliable surrogate endpoint as actual renal function may change in an opposite way. Namely, some therapeutic measures improving microalbuminuria/proteinuria may actually worsen renal function. In case of procedures such as blood pressure lowering or measure of RAS blockade an optimum point on a J-curve may exist.